首页 > 最新文献

BMC Rheumatology最新文献

英文 中文
Face validity and reliability test of the Danish version of the compliance questionnaire rheumatology in patients with early rheumatoid arthritis. 丹麦版风湿病依从性问卷在早期类风湿性关节炎患者中的面部有效性和可靠性测试。
IF 2.2 Q3 RHEUMATOLOGY Pub Date : 2023-10-25 DOI: 10.1186/s41927-023-00364-5
Line Raunsbæk Knudsen, Annette de Thurah

Background: Supporting adherence to medication is an essential part of the treatment and care of patients with rheumatic and musculoskeletal diseases. The Compliance Questionnaire Rheumatology (CQR) measures adherence in rheumatic diseases through 19 items covering drug-taking behaviour to identify the reasons for adhering to treatment and the factors that contribute to suboptimal adherence. The objective of this study was to present the translation of the CQR into Danish and the face validity and reliability test.

Methods: The CQR was translated into Danish according to international guidelines, followed by a face validity test among 10 patients with rheumatoid arthritis in 2009. The test-retest reliability of the Danish CQR was evaluated in 49 patients with rheumatoid arthritis in 2020 - 2021 using the standard error of the measurement (SEM) converted into the minimally detectable change (MDC) and the intraclass correlation coefficient (ICC). Questionnaires were administered with a minimum of 10 days between assessments.

Results: The participants in the reliability test had a mean age of 57.4 years (SD 16.1) and a mean disease duration of 1.13 years (range 2 months-2 years). The mean CQR score in the test and retest was 62.7 (confidence interval (CI) 58.8; 66.6) and 62.5 (CI 58.9; 66.1), respectively, with a SEM of 8.59 (7.16; 10.73) and an MDC of 16.83. A satisfactory test-retest reliability was confirmed by an ICC value of 0.79 (CI 0.68; 0.89).

Conclusion: The Danish CQR has satisfactory test-retest reliability in patients newly diagnosed with rheumatoid arthritis and is considered a reliable tool to measure adherence in this group.

背景:支持坚持用药是风湿性和肌肉骨骼疾病患者治疗和护理的重要组成部分。风湿病依从性问卷(CQR)通过19个项目来衡量风湿病的依从性,包括服药行为,以确定坚持治疗的原因和导致依从性不理想的因素。本研究的目的是介绍CQR到丹麦语的翻译以及面孔的有效性和可靠性测试。方法:根据国际指南将CQR翻译成丹麦语,然后在2009年对10名类风湿性关节炎患者进行面部有效性测试。2020-2021年,使用转换为最小可检测变化(MDC)的标准测量误差(SEM)和组内相关系数(ICC),对49名类风湿性关节炎患者的丹麦CQR的重测可靠性进行了评估。两次评估之间至少间隔10天进行问卷调查。结果:可靠性测试的参与者平均年龄为57.4岁(SD 16.1),平均疾病持续时间为1.13年(范围为2个月-2年)。测试和重新测试中的平均CQR得分为62.7(置信区间(CI)58.8;66.6)和62.5(CI 58.9;66.1),SEM为8.59(7.16;10.73),MDC为16.83。ICC值为0.79(CI 0.68;0.89),证实了令人满意的重新测试可靠性。结论:丹麦CQR在新诊断为类风湿性关节炎的患者中具有令人满意的测试可靠性,被认为是衡量该组患者依从性的可靠工具。
{"title":"Face validity and reliability test of the Danish version of the compliance questionnaire rheumatology in patients with early rheumatoid arthritis.","authors":"Line Raunsbæk Knudsen, Annette de Thurah","doi":"10.1186/s41927-023-00364-5","DOIUrl":"10.1186/s41927-023-00364-5","url":null,"abstract":"<p><strong>Background: </strong>Supporting adherence to medication is an essential part of the treatment and care of patients with rheumatic and musculoskeletal diseases. The Compliance Questionnaire Rheumatology (CQR) measures adherence in rheumatic diseases through 19 items covering drug-taking behaviour to identify the reasons for adhering to treatment and the factors that contribute to suboptimal adherence. The objective of this study was to present the translation of the CQR into Danish and the face validity and reliability test.</p><p><strong>Methods: </strong>The CQR was translated into Danish according to international guidelines, followed by a face validity test among 10 patients with rheumatoid arthritis in 2009. The test-retest reliability of the Danish CQR was evaluated in 49 patients with rheumatoid arthritis in 2020 - 2021 using the standard error of the measurement (SEM) converted into the minimally detectable change (MDC) and the intraclass correlation coefficient (ICC). Questionnaires were administered with a minimum of 10 days between assessments.</p><p><strong>Results: </strong>The participants in the reliability test had a mean age of 57.4 years (SD 16.1) and a mean disease duration of 1.13 years (range 2 months-2 years). The mean CQR score in the test and retest was 62.7 (confidence interval (CI) 58.8; 66.6) and 62.5 (CI 58.9; 66.1), respectively, with a SEM of 8.59 (7.16; 10.73) and an MDC of 16.83. A satisfactory test-retest reliability was confirmed by an ICC value of 0.79 (CI 0.68; 0.89).</p><p><strong>Conclusion: </strong>The Danish CQR has satisfactory test-retest reliability in patients newly diagnosed with rheumatoid arthritis and is considered a reliable tool to measure adherence in this group.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"7 1","pages":"38"},"PeriodicalIF":2.2,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50160587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE). 生物制剂治疗系统性红斑狼疮(SLE)的安全性和有效性。
IF 2.1 Q3 RHEUMATOLOGY Pub Date : 2023-10-09 DOI: 10.1186/s41927-023-00358-3
Justin Chan, Giles D Walters, Prianka Puri, Simon H Jiang

Background: To determine the safety and efficacy of biological agents used in the treatment of systemic lupus erythematosus (SLE) in adults.

Methods: Systematic review and meta-analysis following PRISMA guidelines.

Data sources: MEDLINE (through Pubmed), EMBASE, Cochrane library, Clinicaltrials.gov, Australianclinicaltrials.gov.au, ANZCTR.org.au and WHO International Clinical Trials Registry Platform for studies published from 20 May 2021 and 15 years prior. A grey literature search was performed and completed on 31 May 2021.

Study criteria: Phase II, III or quasi randomised controlled trials, studies with only cerebral or cutaneous lupus were excluded.

Data extraction: Two authors independently screened studies for eligibility, extracted, reviewed data for accuracy, and used the Cochrane tool to assess risk of bias.

Results: Forty-four studies were identified, consisting of 15 groups of drugs and 25 different biological agents, totalling 16,889 patients. The main outcomes assessed included Systemic Lupus Erythematosus Responder Index (SRI), BILAG-Based Composite Lupus Assessment (BICLA) and combined combined/partial renal remission (CRR/PRR). Four groups of biologics were found to improve outcomes. Anti-interferons: Anifrolumab increased BICLA response and SRI 5 to 8, decreased prednisone dosages, with increased herpes zoster infections, but fewer serious adverse events. Sifalimumab improved SRI but also increased herpes zoster infections. Anti BAFF/BLyS and/or APRIL: Belimumab consistently improved SRI 4, decreased prednisone dosages, increased combined CRR/PRR, and had no adverse safety outcomes. Tabalumab increased SRI 5 at 52 weeks with no steroid sparing effect but was associated with increased infusion related adverse events. Telitacicept improved SRI 4 at 52 weeks, with no increased adverse events, though data was rather sparse. Anti CD-20 monoclonal antibody, Obinutuzumab increased combined CRR/PRR at 1 and 2 years. Anti IL12/23 monoclonal antibody, Ustekinumab, increased SRI 4 to 6, but not BICLA at 24 weeks, with no concerning safety outcomes.

Conclusion: Multiple biologic agents are shown in high quality studies to have a significant therapeutic impact on outcomes in SLE.

背景:确定生物制剂治疗成人系统性红斑狼疮(SLE)的安全性和有效性。方法:遵循PRISMA指南进行系统回顾和荟萃分析。数据来源:MEDLINE(通过Pubmed)、EMBASE、Cochrane图书馆、Clinicaltrials.gov、Australianclinicialtrials.gov.au、ANZCTR.org.au和世界卫生组织国际临床试验注册平台,用于2021年5月20日和15年前发布的研究。2021年5月31日进行并完成了灰色文献检索。研究标准:II期、III期或准随机对照试验,仅排除脑或皮肤狼疮的研究。数据提取:两位作者独立筛选研究的合格性,提取并审查数据的准确性,并使用Cochrane工具评估偏倚风险。结果:确定了44项研究,包括15组药物和25种不同的生物制剂,共16889名患者。评估的主要结果包括系统性红斑狼疮反应者指数(SRI)、基于BILAG的综合狼疮评估(BICLA)和联合/部分肾脏缓解(CRR/PRR)。发现四组生物制剂可以改善疗效。抗干扰素:Anifrolumab增加了BICLA反应和SRI 5至8,减少了泼尼松剂量,带状疱疹感染增加,但严重不良事件较少。西法利单抗改善了SRI,但也增加了带状疱疹感染。抗BAFF/BLyS和/或APRIL:Belimumab持续改善SRI4,减少泼尼松剂量,增加联合CRR/PRR,并且没有不良安全性结果。Tabalumab在52周时增加SRI 5,没有类固醇保留作用,但与输液相关不良事件增加有关。Telitacicept在52周时改善了SRI4,没有增加不良事件,尽管数据相当稀少。抗CD-20单克隆抗体,奥比努珠单抗在1年和2年时增加了CRR/PRR。抗IL12/23单克隆抗体Ustekinumab在24周时将SRI增加到4至6,但没有增加BICLA,没有相关的安全性结果。结论:在高质量的研究中,多种生物制剂对SLE的疗效有显著影响。
{"title":"Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE).","authors":"Justin Chan, Giles D Walters, Prianka Puri, Simon H Jiang","doi":"10.1186/s41927-023-00358-3","DOIUrl":"10.1186/s41927-023-00358-3","url":null,"abstract":"<p><strong>Background: </strong>To determine the safety and efficacy of biological agents used in the treatment of systemic lupus erythematosus (SLE) in adults.</p><p><strong>Methods: </strong>Systematic review and meta-analysis following PRISMA guidelines.</p><p><strong>Data sources: </strong>MEDLINE (through Pubmed), EMBASE, Cochrane library, Clinicaltrials.gov, Australianclinicaltrials.gov.au, ANZCTR.org.au and WHO International Clinical Trials Registry Platform for studies published from 20 May 2021 and 15 years prior. A grey literature search was performed and completed on 31 May 2021.</p><p><strong>Study criteria: </strong>Phase II, III or quasi randomised controlled trials, studies with only cerebral or cutaneous lupus were excluded.</p><p><strong>Data extraction: </strong>Two authors independently screened studies for eligibility, extracted, reviewed data for accuracy, and used the Cochrane tool to assess risk of bias.</p><p><strong>Results: </strong>Forty-four studies were identified, consisting of 15 groups of drugs and 25 different biological agents, totalling 16,889 patients. The main outcomes assessed included Systemic Lupus Erythematosus Responder Index (SRI), BILAG-Based Composite Lupus Assessment (BICLA) and combined combined/partial renal remission (CRR/PRR). Four groups of biologics were found to improve outcomes. Anti-interferons: Anifrolumab increased BICLA response and SRI 5 to 8, decreased prednisone dosages, with increased herpes zoster infections, but fewer serious adverse events. Sifalimumab improved SRI but also increased herpes zoster infections. Anti BAFF/BLyS and/or APRIL: Belimumab consistently improved SRI 4, decreased prednisone dosages, increased combined CRR/PRR, and had no adverse safety outcomes. Tabalumab increased SRI 5 at 52 weeks with no steroid sparing effect but was associated with increased infusion related adverse events. Telitacicept improved SRI 4 at 52 weeks, with no increased adverse events, though data was rather sparse. Anti CD-20 monoclonal antibody, Obinutuzumab increased combined CRR/PRR at 1 and 2 years. Anti IL12/23 monoclonal antibody, Ustekinumab, increased SRI 4 to 6, but not BICLA at 24 weeks, with no concerning safety outcomes.</p><p><strong>Conclusion: </strong>Multiple biologic agents are shown in high quality studies to have a significant therapeutic impact on outcomes in SLE.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"7 1","pages":"37"},"PeriodicalIF":2.1,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41116910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The student patient alliance: development and formative evaluation of an initiative to support collaborations between patient and public involvement partners and doctoral students. 学生-患者联盟:支持患者和公众参与伙伴以及博士生之间合作的倡议的发展和形成性评估。
IF 2.2 Q3 RHEUMATOLOGY Pub Date : 2023-10-03 DOI: 10.1186/s41927-023-00359-2
Gwenda Simons, Rebecca Birch, Joanne Stocks, Elspeth Insch, Rob Rijckborst, Georgiana Neag, Heidi McColm, Leigh Romaniuk, Claire Wright, Bethan E Phillips, Simon W Jones, Arthur G Pratt, Stefan Siebert, Karim Raza, Marie Falahee

Background: While the integration of patient and public involvement (PPI) in clinical research is now widespread and recommended as standard practice, meaningful PPI in pre-clinical, discovery science research is more difficult to achieve. One potential way to address this is by integrating PPI into the training programmes of discovery science postgraduate doctoral students. This paper describes the development and formative evaluation of the Student Patient Alliance (SPA), a programme developed at the University of Birmingham that connects PPI partners with doctoral students.

Methods: Following a successful pilot of the SPA by the Rheumatology Research Group at the University of Birmingham, the scheme was implemented across several collaborating Versus Arthritis / Medical Research Council (MRC) centres of excellence. Doctoral students were partnered with PPI partners, provided with initial information and guidance, and then encouraged to work together on research and public engagement activities. After six months, students, their PPI partners and the PPI coordinators at each centre completed brief surveys about their participation in the SPA.

Results: Both doctoral students and their PPI partners felt that taking part in SPA had a positive impact on understanding, motivation and communication skills. Students reported an increased understanding of PPI and patient priorities and reported improved public engagement skills. Their PPI partners reported a positive impact of the collaboration with the students. They enjoyed learning about the student's research and contributing to the student's personal development. PPI coordinators also highlighted the benefits of the SPA, but noted some challenges they had experienced, such as difficulties matching students with PPI partners.

Conclusions: The SPA was valued by students and PPI partners, and it is likely that initiatives of this kind would enhance students' PPI and public engagement skills and awareness of patients' experiences on a wider scale. However, appropriate resources are needed at an institutional level to support the implementation of effective programmes of this kind on a larger scale.

背景:虽然患者和公众参与(PPI)在临床研究中的整合现在很普遍,并被推荐为标准实践,但在临床前、发现科学研究中更难实现有意义的PPI。解决这一问题的一个潜在方法是将PPI纳入发现科学研究生博士生的培训计划。本文描述了学生-患者联盟(SPA)的发展和形成性评估,这是伯明翰大学开发的一个项目,将PPI合作伙伴与博士生联系起来。方法:在伯明翰大学风湿病研究小组成功试点SPA后,该计划在几个合作的Versus关节炎/医学研究委员会(MRC)卓越中心实施。博士生与PPI合作伙伴合作,提供初步信息和指导,然后鼓励他们共同开展研究和公众参与活动。六个月后,学生、他们的PPI合作伙伴和每个中心的PPI协调员完成了关于他们参与SPA的简短调查。学生们报告说,他们对PPI和患者优先事项的理解有所提高,并报告说,公众参与技能有所提高。他们的PPI合作伙伴报告说,与学生的合作产生了积极影响。他们喜欢了解学生的研究,并为学生的个人发展做出贡献。PPI协调员也强调了SPA的好处,但指出了他们所经历的一些挑战,例如难以将学生与PPI合作伙伴匹配。结论:SPA受到学生和PPI合作伙伴的重视,这类举措很可能会在更大范围内提高学生的PPI和公众参与技能以及对患者体验的认识。然而,需要在机构一级提供适当的资源,以支持更大规模地执行这类有效方案。
{"title":"The student patient alliance: development and formative evaluation of an initiative to support collaborations between patient and public involvement partners and doctoral students.","authors":"Gwenda Simons, Rebecca Birch, Joanne Stocks, Elspeth Insch, Rob Rijckborst, Georgiana Neag, Heidi McColm, Leigh Romaniuk, Claire Wright, Bethan E Phillips, Simon W Jones, Arthur G Pratt, Stefan Siebert, Karim Raza, Marie Falahee","doi":"10.1186/s41927-023-00359-2","DOIUrl":"10.1186/s41927-023-00359-2","url":null,"abstract":"<p><strong>Background: </strong>While the integration of patient and public involvement (PPI) in clinical research is now widespread and recommended as standard practice, meaningful PPI in pre-clinical, discovery science research is more difficult to achieve. One potential way to address this is by integrating PPI into the training programmes of discovery science postgraduate doctoral students. This paper describes the development and formative evaluation of the Student Patient Alliance (SPA), a programme developed at the University of Birmingham that connects PPI partners with doctoral students.</p><p><strong>Methods: </strong>Following a successful pilot of the SPA by the Rheumatology Research Group at the University of Birmingham, the scheme was implemented across several collaborating Versus Arthritis / Medical Research Council (MRC) centres of excellence. Doctoral students were partnered with PPI partners, provided with initial information and guidance, and then encouraged to work together on research and public engagement activities. After six months, students, their PPI partners and the PPI coordinators at each centre completed brief surveys about their participation in the SPA.</p><p><strong>Results: </strong>Both doctoral students and their PPI partners felt that taking part in SPA had a positive impact on understanding, motivation and communication skills. Students reported an increased understanding of PPI and patient priorities and reported improved public engagement skills. Their PPI partners reported a positive impact of the collaboration with the students. They enjoyed learning about the student's research and contributing to the student's personal development. PPI coordinators also highlighted the benefits of the SPA, but noted some challenges they had experienced, such as difficulties matching students with PPI partners.</p><p><strong>Conclusions: </strong>The SPA was valued by students and PPI partners, and it is likely that initiatives of this kind would enhance students' PPI and public engagement skills and awareness of patients' experiences on a wider scale. However, appropriate resources are needed at an institutional level to support the implementation of effective programmes of this kind on a larger scale.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"7 1","pages":"36"},"PeriodicalIF":2.2,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41106701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stakeholder perceptions of preventive approaches to rheumatoid arthritis: qualitative study of healthcare professionals' perspectives on predictive and preventive strategies. 利益相关者对类风湿性关节炎预防方法的看法:医疗保健专业人员对预测和预防策略的看法的定性研究。
IF 2.1 Q3 RHEUMATOLOGY Pub Date : 2023-10-03 DOI: 10.1186/s41927-023-00361-8
Imogen Wells, Gwenda Simons, Jasin Philip Kanacherril, Christian D Mallen, Karim Raza, Marie Falahee

Background: There is increasing research interest in the development of preventive treatment for individuals at risk of rheumatoid arthritis (RA). Previous studies have explored the perceptions of at-risk groups and patients about predictive and preventive strategies for RA, but little is known about health care professionals' (HCPs) perspectives.

Methods: One-to-one semi-structured qualitative interviews were conducted (face-to-face or by telephone) with HCPs. Audio recordings of the interviews were transcribed, and the data were analysed by thematic analysis.

Results: Nineteen HCPs (11 female) were interviewed, including ten GPs, six rheumatologists and three rheumatology nurse specialists. The thematic analysis identified four organising themes: 1) Attributes of predictive and preventive approaches; 2) Ethical and psychological concerns; 3) Implementation issues and 4) Learning from management of other conditions. Theme 1 described necessary attributes of predictive and preventive approaches, including the type and performance of predictive tools, the need for a sound evidence base and consideration of risks and benefits associated with preventive treatment. Theme 2 described the ethical and psycho-social concerns that interviewees raised, including the potential negative economic, financial and psychological effects of risk disclosure for 'at-risk' individuals, uncertainty around the development of RA and the potential for benefit associated with the treatments being considered. Theme 3 describes the implementation issues considered, including knowledge and training needs, costs and resource implications of implementing predictive and preventive approaches, the role of different types of HCPs, guidelines and tools needed, and patient characteristics relating to the appropriateness of preventive treatments. Theme 4 describes lessons that could be learned from interviewees' experiences of prediction and prevention in other disease areas, including how preventive treatment is prescribed, existing guidelines and tools for other diseases and issues relating to risk communication.

Conclusions: For successful implementation of predictive and preventative approaches in RA, HCPs need appropriate training about use and interpretation of predictive tools, communication of results to at-risk individuals, and options for intervention. Evidence of cost-efficiency, appropriate resource allocation, adaptation of official guidelines and careful consideration of the at-risk individuals' psycho-social needs are also needed.

背景:人们对开发类风湿性关节炎(RA)高危人群的预防性治疗越来越感兴趣。先前的研究探讨了高危人群和患者对RA预测和预防策略的看法,但对卫生保健专业人员的观点知之甚少。方法:对HCP进行一对一的半结构化定性访谈(面对面或电话)。对访谈录音进行了转录,并通过专题分析对数据进行了分析。结果:19名HCP(11名女性)接受了访谈,其中包括10名全科医生、6名风湿病学家和3名风湿病护理专家。主题分析确定了四个组织主题:1)预测和预防方法的属性;2) 伦理和心理问题;3) 执行问题和4)从其他条件的管理中学习。主题1描述了预测和预防方法的必要属性,包括预测工具的类型和性能、建立健全证据基础的必要性以及考虑与预防性治疗相关的风险和益处。主题2描述了受访者提出的伦理和心理社会问题,包括风险披露对“高危”个人的潜在负面经济、财务和心理影响、RA发展的不确定性以及与正在考虑的治疗相关的潜在益处。主题3描述了所考虑的实施问题,包括知识和培训需求、实施预测性和预防性方法的成本和资源影响、不同类型HCP的作用、所需的指南和工具,以及与预防性治疗适当性相关的患者特征。主题4介绍了可以从受访者在其他疾病领域的预测和预防经验中吸取的教训,包括如何制定预防性治疗,针对其他疾病的现有指南和工具,以及与风险沟通有关的问题。结论:为了在RA中成功实施预测性和预防性方法,HCP需要接受关于预测工具的使用和解释、向高危人群传达结果以及干预选择的适当培训。还需要证明成本效益、适当的资源分配、调整官方指导方针以及仔细考虑高危人群的心理社会需求。
{"title":"Stakeholder perceptions of preventive approaches to rheumatoid arthritis: qualitative study of healthcare professionals' perspectives on predictive and preventive strategies.","authors":"Imogen Wells, Gwenda Simons, Jasin Philip Kanacherril, Christian D Mallen, Karim Raza, Marie Falahee","doi":"10.1186/s41927-023-00361-8","DOIUrl":"10.1186/s41927-023-00361-8","url":null,"abstract":"<p><strong>Background: </strong>There is increasing research interest in the development of preventive treatment for individuals at risk of rheumatoid arthritis (RA). Previous studies have explored the perceptions of at-risk groups and patients about predictive and preventive strategies for RA, but little is known about health care professionals' (HCPs) perspectives.</p><p><strong>Methods: </strong>One-to-one semi-structured qualitative interviews were conducted (face-to-face or by telephone) with HCPs. Audio recordings of the interviews were transcribed, and the data were analysed by thematic analysis.</p><p><strong>Results: </strong>Nineteen HCPs (11 female) were interviewed, including ten GPs, six rheumatologists and three rheumatology nurse specialists. The thematic analysis identified four organising themes: 1) Attributes of predictive and preventive approaches; 2) Ethical and psychological concerns; 3) Implementation issues and 4) Learning from management of other conditions. Theme 1 described necessary attributes of predictive and preventive approaches, including the type and performance of predictive tools, the need for a sound evidence base and consideration of risks and benefits associated with preventive treatment. Theme 2 described the ethical and psycho-social concerns that interviewees raised, including the potential negative economic, financial and psychological effects of risk disclosure for 'at-risk' individuals, uncertainty around the development of RA and the potential for benefit associated with the treatments being considered. Theme 3 describes the implementation issues considered, including knowledge and training needs, costs and resource implications of implementing predictive and preventive approaches, the role of different types of HCPs, guidelines and tools needed, and patient characteristics relating to the appropriateness of preventive treatments. Theme 4 describes lessons that could be learned from interviewees' experiences of prediction and prevention in other disease areas, including how preventive treatment is prescribed, existing guidelines and tools for other diseases and issues relating to risk communication.</p><p><strong>Conclusions: </strong>For successful implementation of predictive and preventative approaches in RA, HCPs need appropriate training about use and interpretation of predictive tools, communication of results to at-risk individuals, and options for intervention. Evidence of cost-efficiency, appropriate resource allocation, adaptation of official guidelines and careful consideration of the at-risk individuals' psycho-social needs are also needed.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"7 1","pages":"35"},"PeriodicalIF":2.1,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41126084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pericardial effusions and cardiac tamponade in hospitalized systemic sclerosis patients: analysis of the national inpatient sample. 住院系统性硬化患者的心包积液和心包填塞:全国住院患者样本分析。
IF 2.2 Q3 RHEUMATOLOGY Pub Date : 2023-09-28 DOI: 10.1186/s41927-023-00360-9
Bikash Basyal, Waqas Ullah, Chris T Derk

Introduction: Clinically significant pericardial effusions and cardiac tamponade in systemic sclerosis (SSc) patients is uncommon and the factors that contribute to progression of pericardial involvement in SSc patients have not been well established.

Methods: A review of the national inpatient sample database was performed looking SSc related hospitalizations between 2002 and 2019. Data was collected on patients with pericardial effusions and cardiac tamponade and analyzed to identify and describe patient characteristics and comorbidities.

Results: Out of a total of 523,410 SSc hospitalizations, with an overall inpatient mortality rate of 4.7% (24,764 patients), pericardial effusion was identified in 3.1% of all hospitalizations (16,141 patients) out of which 0.2% (838 patients) had a diagnosis of cardiac tamponade. Patients with pericardial effusion were significantly more likely to have pulmonary circulatory disease (p = < 0.0001), congestive heart failure (p = < 0.0001) end stage renal disease (p = < 0.0001), diabetes (p = 0.015), and hypothyroidism (p = 0.025). Patients with cardiac tamponade were significantly more likely to have a history of coronary artery bypass graft surgery (p = 0.001) or atrial fibrillation (p = < 0.0001). Hospitalized patients with cardiac tamponade had a significantly increased mortality rate of 17.7% compared to 8.8% in patients with pericardial effusions without a tamponade physiology, with an odds ratio of 2.3 (1.97-2.86), p = < 0.0001.

Conclusion: Pericardial effusion and tamponade are associated with increased morbidity and mortality in SSc patients. Further studies are required to explore the role of patient comorbidities and characteristics in development into pericardial effusions or tamponade.

引言:在系统性硬化症(SSc)患者中,具有临床意义的心包积液和心脏填塞并不常见,导致SSc患者心包受累进展的因素尚未明确。方法:对2002年至2019年间与SSc相关的全国住院患者样本数据库进行审查。收集心包积液和心脏压塞患者的数据,并进行分析,以确定和描述患者特征和合并症。结果:在523410例SSc住院患者中,总住院死亡率为4.7%(24764名患者),3.1%的住院患者(16141名患者)发现心包积液,其中0.2%(838名患者)被诊断为心脏压塞。心包积液患者更容易患肺循环系统疾病(p = 结论:心包积液和填塞与SSc患者的发病率和死亡率增加有关。需要进一步的研究来探索患者合并症和特征在发展为心包积液或心包填塞中的作用。
{"title":"Pericardial effusions and cardiac tamponade in hospitalized systemic sclerosis patients: analysis of the national inpatient sample.","authors":"Bikash Basyal, Waqas Ullah, Chris T Derk","doi":"10.1186/s41927-023-00360-9","DOIUrl":"10.1186/s41927-023-00360-9","url":null,"abstract":"<p><strong>Introduction: </strong>Clinically significant pericardial effusions and cardiac tamponade in systemic sclerosis (SSc) patients is uncommon and the factors that contribute to progression of pericardial involvement in SSc patients have not been well established.</p><p><strong>Methods: </strong>A review of the national inpatient sample database was performed looking SSc related hospitalizations between 2002 and 2019. Data was collected on patients with pericardial effusions and cardiac tamponade and analyzed to identify and describe patient characteristics and comorbidities.</p><p><strong>Results: </strong>Out of a total of 523,410 SSc hospitalizations, with an overall inpatient mortality rate of 4.7% (24,764 patients), pericardial effusion was identified in 3.1% of all hospitalizations (16,141 patients) out of which 0.2% (838 patients) had a diagnosis of cardiac tamponade. Patients with pericardial effusion were significantly more likely to have pulmonary circulatory disease (p = < 0.0001), congestive heart failure (p = < 0.0001) end stage renal disease (p = < 0.0001), diabetes (p = 0.015), and hypothyroidism (p = 0.025). Patients with cardiac tamponade were significantly more likely to have a history of coronary artery bypass graft surgery (p = 0.001) or atrial fibrillation (p = < 0.0001). Hospitalized patients with cardiac tamponade had a significantly increased mortality rate of 17.7% compared to 8.8% in patients with pericardial effusions without a tamponade physiology, with an odds ratio of 2.3 (1.97-2.86), p = < 0.0001.</p><p><strong>Conclusion: </strong>Pericardial effusion and tamponade are associated with increased morbidity and mortality in SSc patients. Further studies are required to explore the role of patient comorbidities and characteristics in development into pericardial effusions or tamponade.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"7 1","pages":"34"},"PeriodicalIF":2.2,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41114929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation of a hybrid healthcare model in rheumatic musculoskeletal diseases: 6-months results of the multicenter Digireuma study. 风湿性肌肉骨骼疾病混合医疗模式的实施:多中心Digireuma研究的6个月结果。
IF 2.2 Q3 RHEUMATOLOGY Pub Date : 2023-09-25 DOI: 10.1186/s41927-023-00362-7
D Benavent, L Fernández-Luque, M Sanz-Jardón, I Bilionis, M Novella-Navarro, V Navarro-Compán, P L González-Sanz, E Calvo, L Lojo, A Balsa, Ch Plasencia-Rodríguez

Objectives: Rheumatic and musculoskeletal diseases (RMDs) require a tailored follow-up that can be enhanced by the implementation of innovative tools. The Digireuma study aimed to test the feasibility of a hybrid follow-up utilizing an electronic patient reported outcomes (ePROs)-based monitoring strategy in patients with RMDs.

Methods: Adult patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) were recruited for a 6-month bicentric prospective follow-up consisting of face-to-face and digital assessments. Patients were asked to report disease-specific ePROs on a pre-established basis, and could also report flares, medication changes, and recent infections at any time. Four rheumatologists monitored these outcomes and contacted patients for interventions when deemed necessary. Results from face-to-face and digital assessments were described.

Results: Of 56 recruited patients, 47 (84%) submitted any ePROs to the digital platform. Most patients with RA were female (74%, median age of 47 years), while 48% of patients with SpA were female (median age 40.4 years). A total of 3,800 platform visits were completed, with a median of 57 and 29 visits in patients with RA and SpA, respectively. Among 52 reported alerts, 47 (90%) needed contact, of which 36 (77%) were managed remotely. Adherence rates declined throughout the study, with around half of patients dropping out during the 6 months follow-up.

Conclusion: The implementation of a hybrid follow-up in clinical practice is feasible. Digital health solutions can provide granular knowledge of disease evolution and enable more informed clinical decision making, leading to improved patient outcomes. Further research is needed to identify target patient populations and engagement strategies.

目标:类风湿和肌肉骨骼疾病(RMD)需要有针对性的随访,可以通过实施创新工具来加强随访。Digireuma研究旨在测试在RMD患者中使用基于电子患者报告结果(ePRO)的监测策略进行混合随访的可行性。方法:招募患有类风湿性关节炎(RA)和脊椎关节炎(SpA)的成年患者进行为期6个月的双中心前瞻性随访,包括面对面和数字评估。患者被要求在预先确定的基础上报告疾病特异性ePRO,还可以随时报告发作、药物变化和最近的感染。四位风湿病学家监测了这些结果,并在必要时联系患者进行干预。介绍了面对面和数字评估的结果。结果:在56名招募的患者中,47人(84%)向数字平台提交了任何ePRO。大多数RA患者为女性(74%,中位年龄47岁),而SpA患者中有48%为女性(中位年龄40.4岁)。共完成3800次平台访问,RA和SpA患者的中位访问分别为57次和29次。在52个报告的警报中,47个(90%)需要联系,其中36个(77%)是远程管理的。在整个研究过程中,依从性下降,大约一半的患者在6个月的随访中退出。结论:在临床实践中实施混合随访是可行的。数字健康解决方案可以提供疾病演变的精细知识,并实现更明智的临床决策,从而改善患者的预后。需要进一步的研究来确定目标患者群体和参与策略。
{"title":"Implementation of a hybrid healthcare model in rheumatic musculoskeletal diseases: 6-months results of the multicenter Digireuma study.","authors":"D Benavent, L Fernández-Luque, M Sanz-Jardón, I Bilionis, M Novella-Navarro, V Navarro-Compán, P L González-Sanz, E Calvo, L Lojo, A Balsa, Ch Plasencia-Rodríguez","doi":"10.1186/s41927-023-00362-7","DOIUrl":"10.1186/s41927-023-00362-7","url":null,"abstract":"<p><strong>Objectives: </strong>Rheumatic and musculoskeletal diseases (RMDs) require a tailored follow-up that can be enhanced by the implementation of innovative tools. The Digireuma study aimed to test the feasibility of a hybrid follow-up utilizing an electronic patient reported outcomes (ePROs)-based monitoring strategy in patients with RMDs.</p><p><strong>Methods: </strong>Adult patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) were recruited for a 6-month bicentric prospective follow-up consisting of face-to-face and digital assessments. Patients were asked to report disease-specific ePROs on a pre-established basis, and could also report flares, medication changes, and recent infections at any time. Four rheumatologists monitored these outcomes and contacted patients for interventions when deemed necessary. Results from face-to-face and digital assessments were described.</p><p><strong>Results: </strong>Of 56 recruited patients, 47 (84%) submitted any ePROs to the digital platform. Most patients with RA were female (74%, median age of 47 years), while 48% of patients with SpA were female (median age 40.4 years). A total of 3,800 platform visits were completed, with a median of 57 and 29 visits in patients with RA and SpA, respectively. Among 52 reported alerts, 47 (90%) needed contact, of which 36 (77%) were managed remotely. Adherence rates declined throughout the study, with around half of patients dropping out during the 6 months follow-up.</p><p><strong>Conclusion: </strong>The implementation of a hybrid follow-up in clinical practice is feasible. Digital health solutions can provide granular knowledge of disease evolution and enable more informed clinical decision making, leading to improved patient outcomes. Further research is needed to identify target patient populations and engagement strategies.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"7 1","pages":"32"},"PeriodicalIF":2.2,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41122837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heterogeneity of treatment responses in rheumatoid arthritis using group based trajectory models: secondary analysis of clinical trial data. 使用基于组的轨迹模型对类风湿性关节炎治疗反应的异质性:临床试验数据的二次分析。
IF 2.2 Q3 RHEUMATOLOGY Pub Date : 2023-09-25 DOI: 10.1186/s41927-023-00348-5
Fowzia Ibrahim, Ian C Scott, David L Scott, Salma Ahmed Ayis

Background: Traditionally rheumatoid arthritis (RA) trials classify patients as responders and non-responders; they ignore the potential range of treatment responses. Group Based Trajectory Models (GBTMs) provide a more refined approach. They identify patient subgroups with similar outcome trajectories. We used GBTMs to classify patients into subgroups of varying responses and explore factors associated with different responses to intensive treatment in a secondary analysis of intensive treatment in the TITRATE clinical trial.

Methods: The TITRATE trial enrolled 335 patients with RA: 168 patients were randomised to receive intensive management, which comprised monthly assessments including measures of the disease activity score for 28 joints (DAS28), treatment escalation when patients were not responding sufficiently and psychosocial support; 163 of these patients completed the trial. We applied GBTMs to monthly DAS28 scores over one year to these patients who had received intensive management. The control group had standard care and were assessed every 6 months; they had too few DAS28 scores for applying GBTMs.

Results: GBTMs identified three distinct trajectories in the patients receiving intensive management: good (n = 40), moderate (n = 76) and poor (n = 47) responders. Baseline body mass index (BMI), disability, fatigue and depression levels were significantly different between trajectory groups. Few (10%) good responders were obese, compared to 38% of moderate, and 43% of poor responders (P = 0.002). Few (8%) good responders had depression, compared to 14% moderate responders, and 38% poor responders (P < 0.001). The key difference in treatments was using high-cost biologics, used in only 5% of good responders but 30% of moderate and 51% of poor responders (P < 0.001). Most good responders had endpoint remissions and low disability, pain, and fatigue scores; few poor responders achieved any favourable outcomes.

Conclusion: GBTMs identified three trajectories of disease activity progression in patients receiving intensive management for moderately active RA. Baseline variables like obesity and depression predicted different treatment responses. Few good responders needed biologic drugs; they responded to conventional DMARDs alone. GBTMs have the potential to facilitate precision medicine enabling patient-oriented treatment strategies based on key characteristics.

Registration: TITRATE Trial ISRCTN 70160382.

背景:传统的类风湿性关节炎(RA)试验将患者分为有反应者和无反应者;他们忽略了治疗反应的潜在范围。基于组的轨迹模型(GBTM)提供了一种更精细的方法。他们确定了具有相似结果轨迹的患者亚组。我们使用GBTM将患者分为不同反应的亚组,并在TITRATE临床试验中对强化治疗的二次分析中探讨与强化治疗不同反应相关的因素。方法:TITRATE试验纳入335名RA患者:168名患者随机接受强化治疗,包括每月评估,包括28个关节的疾病活动评分(DAS28)、患者反应不足时的治疗升级和心理社会支持;其中163名患者完成了试验。我们将GBTM应用于这些接受强化治疗的患者一年内的每月DAS28评分。对照组接受标准护理,每6个月进行一次评估;结果:GBTM在接受强化治疗的患者中发现了三个不同的轨迹:良好(n = 40),中度(n = 76)和差(n = 47)响应者。基线体重指数(BMI)、残疾、疲劳和抑郁水平在轨迹组之间存在显著差异。很少(10%)反应良好的人肥胖,而中等反应者和不良反应者分别为38%和43%(P = 0.002)。很少有(8%)好的应答者患有抑郁症,相比之下,14%的中度应答者和38%的不良应答者(P 结论:GBTMs确定了接受中度活动性RA强化治疗的患者疾病活动进展的三个轨迹。肥胖和抑郁等基线变量预测了不同的治疗反应。很少有好的反应者需要生物药物;它们单独对常规DMARD作出反应。GBTM有可能促进精准医疗,从而实现基于关键特征的以患者为导向的治疗策略。注册:TITRATE试验ISRCTN 70160382。
{"title":"Heterogeneity of treatment responses in rheumatoid arthritis using group based trajectory models: secondary analysis of clinical trial data.","authors":"Fowzia Ibrahim, Ian C Scott, David L Scott, Salma Ahmed Ayis","doi":"10.1186/s41927-023-00348-5","DOIUrl":"10.1186/s41927-023-00348-5","url":null,"abstract":"<p><strong>Background: </strong>Traditionally rheumatoid arthritis (RA) trials classify patients as responders and non-responders; they ignore the potential range of treatment responses. Group Based Trajectory Models (GBTMs) provide a more refined approach. They identify patient subgroups with similar outcome trajectories. We used GBTMs to classify patients into subgroups of varying responses and explore factors associated with different responses to intensive treatment in a secondary analysis of intensive treatment in the TITRATE clinical trial.</p><p><strong>Methods: </strong>The TITRATE trial enrolled 335 patients with RA: 168 patients were randomised to receive intensive management, which comprised monthly assessments including measures of the disease activity score for 28 joints (DAS28), treatment escalation when patients were not responding sufficiently and psychosocial support; 163 of these patients completed the trial. We applied GBTMs to monthly DAS28 scores over one year to these patients who had received intensive management. The control group had standard care and were assessed every 6 months; they had too few DAS28 scores for applying GBTMs.</p><p><strong>Results: </strong>GBTMs identified three distinct trajectories in the patients receiving intensive management: good (n = 40), moderate (n = 76) and poor (n = 47) responders. Baseline body mass index (BMI), disability, fatigue and depression levels were significantly different between trajectory groups. Few (10%) good responders were obese, compared to 38% of moderate, and 43% of poor responders (P = 0.002). Few (8%) good responders had depression, compared to 14% moderate responders, and 38% poor responders (P < 0.001). The key difference in treatments was using high-cost biologics, used in only 5% of good responders but 30% of moderate and 51% of poor responders (P < 0.001). Most good responders had endpoint remissions and low disability, pain, and fatigue scores; few poor responders achieved any favourable outcomes.</p><p><strong>Conclusion: </strong>GBTMs identified three trajectories of disease activity progression in patients receiving intensive management for moderately active RA. Baseline variables like obesity and depression predicted different treatment responses. Few good responders needed biologic drugs; they responded to conventional DMARDs alone. GBTMs have the potential to facilitate precision medicine enabling patient-oriented treatment strategies based on key characteristics.</p><p><strong>Registration: </strong>TITRATE Trial ISRCTN 70160382.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"7 1","pages":"33"},"PeriodicalIF":2.2,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41111044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness and cost-effectiveness of a multimodal, physiotherapist-led, vocational intervention in people with inflammatory arthritis: study protocol of the Physiotherapy WORKs trial. 多模式、物理治疗师主导的职业干预对炎症性关节炎患者的有效性和成本效益:物理疗法WORKs试验的研究方案。
IF 2.2 Q3 RHEUMATOLOGY Pub Date : 2023-09-20 DOI: 10.1186/s41927-023-00357-4
N F Bakker, S F E van Weely, N Hutting, Y F Heerkens, J A Engels, J B Staal, M van der Leeden, A Boonen, W B van den Hout, T P M Vliet Vlieland, J Knoop

Background: Although reduced work ability is a substantial problem among people with inflammatory arthritis (IA), work ability is an underexposed area in clinical practice. Evidence on vocational interventions in IA is limited, but favourable results of delivery by a physiotherapist (PT) warrant the need for further research. Therefore, we aim to evaluate the (cost-)effectiveness of a multimodal, PT-led, vocational intervention in (self-)employed people with IA compared to usual care.

Methods: This randomized controlled trial will include 140 people with rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA) who are (self-)employed and have reduced work ability (Work Ability Index - Single Item Scale (WAS) ≤ 7/10) and/or RA/axSpA related sick leave (≤ 6 months). Participants will be randomized 1:1 to the intervention or control condition (usual care). The intervention, delivered by primary care PTs, will be personalized to each patient, consisting of 10 to 21 sessions over 12 months. The intervention will be multimodal, comprising of 1) exercise therapy and a physical activity plan, 2) education/self-management support, 3) work-roadmap to guide participants in finding relevant other care, with optionally 4) online self-management course and 5) workplace examination. Assessments will be performed at baseline and after 3, 6, and 12 months. The primary outcome measure of effectiveness is work ability, as measured with the WAS at 12 months. For the cost-effectiveness analysis, the EuroQol (EQ-5D-5L), self-reported healthcare use, sick leave and productivity while at work will be used to estimate the trial based cost-utility from a societal perspective. A process evaluation, including assessments of adherence and treatment fidelity, will be undertaken using the registrations of the PTs and semi-structured interviews at 12 months follow-up in a random sample of the intervention group.

Discussion: The results of this study will provide insights in the (cost-)effectiveness of a multimodal, PT-led, vocational intervention in people with IA and a reduced work ability.

Trial registration: This study is registered in the International Clinical Trial Registry Platform (ICTRP) under number NL9343.

背景:尽管工作能力下降是炎症性关节炎(IA)患者的一个严重问题,但在临床实践中,工作能力是一个暴露不足的领域。关于IA职业干预的证据有限,但理疗师(PT)提供的有利结果证明需要进一步研究。因此,与常规护理相比,我们的目的是评估多模式、PT主导的职业干预对(自营)就业IA患者的(成本)有效性。方法:这项随机对照试验将包括140名类风湿性关节炎(RA)或轴性脊椎关节炎(axSpA)患者,他们(自营)工作,工作能力下降(工作能力指数-单项量表(WAS) ≤ 7/10)和/或RA/axSpA相关病假(≤ 6个月)。参与者将被1:1随机分配到干预或对照条件下(常规护理)。由初级保健PT提供的干预措施将针对每位患者进行个性化,包括12个月内的10至21次治疗。干预将是多模式的,包括1)运动治疗和体育活动计划,2)教育/自我管理支持,3)指导参与者寻找相关其他护理的工作路线图,以及可选的4)在线自我管理课程和5)工作场所检查。评估将在基线以及3、6和12个月后进行。有效性的主要结果衡量标准是工作能力,在12个月时用WAS进行测量。对于成本效益分析,EuroQol(EQ-5D-5L)、自我报告的医疗保健使用、病假和工作时的生产力将用于从社会角度估计基于试验的成本效用。过程评估,包括依从性和治疗保真度的评估,将在干预组的随机样本中使用PT的注册和12个月随访时的半结构化访谈进行。讨论:这项研究的结果将为多模式、PT主导的职业干预对IA和工作能力下降的人的(成本)有效性提供见解。试验注册:本研究在国际临床试验注册平台(ICTRP)注册,编号为NL9343。
{"title":"Effectiveness and cost-effectiveness of a multimodal, physiotherapist-led, vocational intervention in people with inflammatory arthritis: study protocol of the Physiotherapy WORKs trial.","authors":"N F Bakker, S F E van Weely, N Hutting, Y F Heerkens, J A Engels, J B Staal, M van der Leeden, A Boonen, W B van den Hout, T P M Vliet Vlieland, J Knoop","doi":"10.1186/s41927-023-00357-4","DOIUrl":"10.1186/s41927-023-00357-4","url":null,"abstract":"<p><strong>Background: </strong>Although reduced work ability is a substantial problem among people with inflammatory arthritis (IA), work ability is an underexposed area in clinical practice. Evidence on vocational interventions in IA is limited, but favourable results of delivery by a physiotherapist (PT) warrant the need for further research. Therefore, we aim to evaluate the (cost-)effectiveness of a multimodal, PT-led, vocational intervention in (self-)employed people with IA compared to usual care.</p><p><strong>Methods: </strong>This randomized controlled trial will include 140 people with rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA) who are (self-)employed and have reduced work ability (Work Ability Index - Single Item Scale (WAS) ≤ 7/10) and/or RA/axSpA related sick leave (≤ 6 months). Participants will be randomized 1:1 to the intervention or control condition (usual care). The intervention, delivered by primary care PTs, will be personalized to each patient, consisting of 10 to 21 sessions over 12 months. The intervention will be multimodal, comprising of 1) exercise therapy and a physical activity plan, 2) education/self-management support, 3) work-roadmap to guide participants in finding relevant other care, with optionally 4) online self-management course and 5) workplace examination. Assessments will be performed at baseline and after 3, 6, and 12 months. The primary outcome measure of effectiveness is work ability, as measured with the WAS at 12 months. For the cost-effectiveness analysis, the EuroQol (EQ-5D-5L), self-reported healthcare use, sick leave and productivity while at work will be used to estimate the trial based cost-utility from a societal perspective. A process evaluation, including assessments of adherence and treatment fidelity, will be undertaken using the registrations of the PTs and semi-structured interviews at 12 months follow-up in a random sample of the intervention group.</p><p><strong>Discussion: </strong>The results of this study will provide insights in the (cost-)effectiveness of a multimodal, PT-led, vocational intervention in people with IA and a reduced work ability.</p><p><strong>Trial registration: </strong>This study is registered in the International Clinical Trial Registry Platform (ICTRP) under number NL9343.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"7 1","pages":"31"},"PeriodicalIF":2.2,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41111043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac sarcoma presenting as paraneoplastic arthritis and clubbing: a case report and literature review. 心脏肉瘤表现为副肿瘤性关节炎及棒状:1例报告及文献复习。
IF 2.2 Q3 RHEUMATOLOGY Pub Date : 2023-09-15 DOI: 10.1186/s41927-023-00350-x
Natasha Ung, Carmella Gunasingam, Ken Cai, Nicholas Manolios, Angela Bayly, Phuong Dinh, Yishay Orr, Preeti Choudhary, Peter Wong

Background: Cardiac tumours are rare, and clinical manifestations depend on the anatomical location. Symptoms can be the result of cardiac outflow anomalies, constitutional features such as fever, loss of weight, and/or paraneoplastic manifestations such as arthritis. To date, there has only been one other case report in the literature of cardiac sarcoma presenting as paraneoplastic arthropathy.

Case presentation: A 52-year-old woman presented with acute onset corticosteroid-resistant inflammatory polyarthralgia, clubbing and a systolic murmur. Transthoracic echocardiogram revealed a dilated left atrium with an echogenic mass and brain magnetic resonance imaging revealed multiple embolic infarcts. Histopathology following emergency resection showed a Grade 3 left atrial intimal sarcoma. The polyarthralgia and clubbing resolved soon after tumour removal. The patient went on to receive chemotherapy and remains in remission.

Conclusions: This case highlights the rare paraneoplastic association of cardiac sarcoma and arthropathy.

背景:心脏肿瘤是罕见的,临床表现取决于解剖位置。症状可由心流出异常、发热、体重减轻等体质特征和/或副肿瘤表现(如关节炎)引起。到目前为止,文献中只有一例心脏肉瘤表现为副肿瘤关节病。病例介绍:一名52岁女性表现为急性发作的皮质类固醇抵抗性炎症性多关节痛,棒状和收缩期杂音。经胸超声心动图显示左心房扩张伴回声肿块,脑磁共振成像显示多发栓塞性梗死。急诊切除后的组织病理学显示为3级左心房内膜肉瘤。多关节痛和杵状痛在肿瘤切除后很快消失。病人继续接受化疗,目前仍处于缓解期。结论:本病例强调了罕见的心脏肉瘤与关节病的副肿瘤关联。
{"title":"Cardiac sarcoma presenting as paraneoplastic arthritis and clubbing: a case report and literature review.","authors":"Natasha Ung, Carmella Gunasingam, Ken Cai, Nicholas Manolios, Angela Bayly, Phuong Dinh, Yishay Orr, Preeti Choudhary, Peter Wong","doi":"10.1186/s41927-023-00350-x","DOIUrl":"10.1186/s41927-023-00350-x","url":null,"abstract":"<p><strong>Background: </strong>Cardiac tumours are rare, and clinical manifestations depend on the anatomical location. Symptoms can be the result of cardiac outflow anomalies, constitutional features such as fever, loss of weight, and/or paraneoplastic manifestations such as arthritis. To date, there has only been one other case report in the literature of cardiac sarcoma presenting as paraneoplastic arthropathy.</p><p><strong>Case presentation: </strong>A 52-year-old woman presented with acute onset corticosteroid-resistant inflammatory polyarthralgia, clubbing and a systolic murmur. Transthoracic echocardiogram revealed a dilated left atrium with an echogenic mass and brain magnetic resonance imaging revealed multiple embolic infarcts. Histopathology following emergency resection showed a Grade 3 left atrial intimal sarcoma. The polyarthralgia and clubbing resolved soon after tumour removal. The patient went on to receive chemotherapy and remains in remission.</p><p><strong>Conclusions: </strong>This case highlights the rare paraneoplastic association of cardiac sarcoma and arthropathy.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"7 1","pages":"30"},"PeriodicalIF":2.2,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10277893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation of serum subfatin, cthrc1, ctrp3, ctrp6 levels with disease indices in patients with axial spondyloarthritis. 轴型脊柱炎患者血清亚脂肪素、cthrc1、ctrp3、ctrp6水平与疾病指标的相关性
IF 2.2 Q3 RHEUMATOLOGY Pub Date : 2023-09-14 DOI: 10.1186/s41927-023-00356-5
I Merve B Uçar, Gökhan Sargin, Ayça Tuzcu, Songül Çildağ, Taşkın Şentürk

Background: The study aimed to investigate novel biomarkers from the C1q TNF superfamily and evaluate their role in autoimmune inflammatory rheumatic diseases with the goal of identifying an effective biomarker to measure clinical disease activity and assess treatment efficacy.

Methods: Sixty-one Axial spondyloarthritis (AxSpa) patients and 30 healthy controls were enrolled in the study. The serum biomarkers subfatin, CTHRC1, CTRP3, CTRP6, IL-6, IL-17, and TNF-α and the disease indices BASDAI, BASFI, MASES, and ASDAS-ESR/CRP were evaluated and compared. The patients were then classified, and their serum biomarkers were assessed according to their ASDAS scores and their treatment regimens.

Results: Among the studied biomarkers, none showed a significant difference between the patients and the healthy controls. Although the difference was not statistically significant, the median values of serum subfatin, CTHRC1, CTRP3, CTRP6, IL-6, IL-17, and TNF-α were all found to be lower in the AxSpa patients than in the healthy controls. Furthermore, once the patients were classified regarding their disease activity, no correlation between the study biomarkers and levels of clinical disease indices was observed. Finally, biological treatments were found to affect the serum concentration of these biomarkers regardless of the level of disease activity.

Conclusion: Novel adipokines and known modulators of inflammation, circulating subfatin, CTHRC1, CTRP3, CTRP6, IL-6, IL-17, and TNF-α levels may play a role in assessing treatment efficacy, especially in those treated with TNF-inhibitors. However, we failed to demonstrate a correlation between clinical disease activity and serum biomarker levels.

背景:本研究旨在研究来自C1q TNF超家族的新型生物标志物,并评估其在自身免疫性炎症性风湿性疾病中的作用,目的是确定一种有效的生物标志物来测量临床疾病活动性和评估治疗效果。方法:选取61例轴性脊柱炎(AxSpa)患者和30名健康对照者。评估并比较两组患者血清生物标志物亚脂肪素、CTHRC1、CTRP3、CTRP6、IL-6、IL-17、TNF-α及疾病指标BASDAI、BASFI、MASES、ASDAS-ESR/CRP。然后对患者进行分类,并根据他们的ASDAS评分和治疗方案评估他们的血清生物标志物。结果:在所研究的生物标志物中,患者与健康对照组之间没有显着差异。虽然差异无统计学意义,但AxSpa患者血清亚脂肪素、CTHRC1、CTRP3、CTRP6、IL-6、IL-17和TNF-α的中位数均低于健康对照组。此外,一旦患者根据其疾病活动进行分类,研究生物标志物与临床疾病指标水平之间没有相关性。最后,发现无论疾病活动水平如何,生物治疗都会影响这些生物标志物的血清浓度。结论:新的脂肪因子和已知的炎症调节剂、循环亚脂肪素、CTHRC1、CTRP3、CTRP6、IL-6、IL-17和TNF-α水平可能在评估治疗效果中发挥作用,特别是在使用TNF抑制剂治疗的患者中。然而,我们未能证明临床疾病活动性与血清生物标志物水平之间的相关性。
{"title":"Correlation of serum subfatin, cthrc1, ctrp3, ctrp6 levels with disease indices in patients with axial spondyloarthritis.","authors":"I Merve B Uçar, Gökhan Sargin, Ayça Tuzcu, Songül Çildağ, Taşkın Şentürk","doi":"10.1186/s41927-023-00356-5","DOIUrl":"10.1186/s41927-023-00356-5","url":null,"abstract":"<p><strong>Background: </strong>The study aimed to investigate novel biomarkers from the C1q TNF superfamily and evaluate their role in autoimmune inflammatory rheumatic diseases with the goal of identifying an effective biomarker to measure clinical disease activity and assess treatment efficacy.</p><p><strong>Methods: </strong>Sixty-one Axial spondyloarthritis (AxSpa) patients and 30 healthy controls were enrolled in the study. The serum biomarkers subfatin, CTHRC1, CTRP3, CTRP6, IL-6, IL-17, and TNF-α and the disease indices BASDAI, BASFI, MASES, and ASDAS-ESR/CRP were evaluated and compared. The patients were then classified, and their serum biomarkers were assessed according to their ASDAS scores and their treatment regimens.</p><p><strong>Results: </strong>Among the studied biomarkers, none showed a significant difference between the patients and the healthy controls. Although the difference was not statistically significant, the median values of serum subfatin, CTHRC1, CTRP3, CTRP6, IL-6, IL-17, and TNF-α were all found to be lower in the AxSpa patients than in the healthy controls. Furthermore, once the patients were classified regarding their disease activity, no correlation between the study biomarkers and levels of clinical disease indices was observed. Finally, biological treatments were found to affect the serum concentration of these biomarkers regardless of the level of disease activity.</p><p><strong>Conclusion: </strong>Novel adipokines and known modulators of inflammation, circulating subfatin, CTHRC1, CTRP3, CTRP6, IL-6, IL-17, and TNF-α levels may play a role in assessing treatment efficacy, especially in those treated with TNF-inhibitors. However, we failed to demonstrate a correlation between clinical disease activity and serum biomarker levels.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"7 1","pages":"29"},"PeriodicalIF":2.2,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10625938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
BMC Rheumatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1